Explanation: This chart presents a synthetic, illustrative view of treatment efficacy by age group for a hypothetical customized onychomycosis solution. The data dimension is Age Group, with five cohorts: 18-29, 30-39, 40-49, 50-59, and 60+. Efficacy is expressed as the percentage of patients achieving complete nail clearance within a fixed follow-up window, scaled from 0 to 100 percent. The values used here (78, 85, 70, 88, 74) form a plausible pattern where the highest clearance occurs in the 50–59 group, while the 40–49 group trails behind. This pattern could reflect differences in nail thickness, regimen adherence, and biological penetration at varying ages when a customized formulation is applied. The example uses a balanced dataset of 50 patients per age band, totaling 250 patients, to avoid extreme distortions from uneven group sizes. It is important to emphasize that this is a synthetic illustration designed to convey relative performance, not a report from a real clinical trial.

The chart is meant to support dimension-focused comparison, highlighting how a tailored solution might offer greater benefits for certain subpopulations. In practice, decision makers would pair such visuals with confidence intervals, p-values, and patient characteristics to assess statistical significance and potential heterogeneity of treatment effects. The 50–59 cohort’s peak suggests that the combination of formulation science and penetration enhancers could be particularly effective for nails with longer disease duration or greater keratin density, while younger groups may respond differently due to shorter disease course or different nail growth dynamics. The visualization also shows that while there is variation by age, the overall efficacy remains relatively high across groups, indicating that a well-designed customized solution has the potential to improve outcomes broadly.

Limitations of this depiction include its synthetic nature, the modest sample size, and the absence of longitudinal relapse data. Real-world results would require rigorous study design, randomized controls, adherence monitoring, and stratified analyses. Despite these caveats, the chart demonstrates how a single dimension—age—can illuminate where innovation in antifungal therapy yields the strongest benefits and where further optimization may be warranted.